Comparative Pharmacology
Head-to-head clinical analysis: FEMCON FE versus GILDESS 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMCON FE versus GILDESS 1 5 30.
FEMCON FE vs GILDESS 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone and ethinyl estradiol. Inhibits ovulation via suppression of gonadotropins (FSH, LH); increases cervical mucus viscosity, impairing sperm penetration; alters endometrial receptivity.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.
One tablet (norethindrone 0.5 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days.
One tablet orally once daily at the same time each day.
None Documented
None Documented
The terminal elimination half-life of ethinyl estradiol is 13-18 hours; for norethindrone, it is 7-12 hours. Both allow once-daily dosing for contraceptive efficacy.
Ethinylestradiol: terminal half-life 13-17 hours (mean 15 h). Desogestrel active metabolite 3-keto-desogestrel: terminal half-life 23-28 hours (mean 25 h). Clinical: steady-state achieved by cycle day 7-10; missed pill instructions based on half-life.
Renal excretion accounts for approximately 40-60% of the dose as metabolites; fecal excretion is about 20-30% via bile. Unchanged drug excretion is minimal.
Renal: ~55-60% as ethinylestradiol glucuronide and sulfate conjugates; ~40% as desogestrel metabolites (largely as 3-keto-desogestrel glucuronide). Fecal: ~30-35% of desogestrel metabolites; <5% for ethinylestradiol. Biliary: minor for both.
Category C
Category C
Oral Contraceptive
Oral Contraceptive